NCT00238394View on ClinicalTrials.gov

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2007

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
Interventions
DRUG

cediranib maleate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00238394 - Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter